Disease Biomarkers in Multiple Sclerosis

@article{Harris2012DiseaseBI,
  title={Disease Biomarkers in Multiple Sclerosis},
  author={Violaine K Harris and Saud Ahmed Sadiq},
  journal={Molecular Diagnosis \& Therapy},
  year={2012},
  volume={13},
  pages={225-244}
}
Multiple sclerosis (MS) is an autoimmune disorder of the brain and spinal cord that predominantly affects white matter. MS has a variable clinical presentation and has no ‘diagnostic’ laboratory test; this often results in delays to definite diagnosis. In confronting the disease, early diagnosis and appropriate, timely therapeutic intervention are critical factors in ensuring favorable long-term outcomes.The availability of reliable biomarkers could radically alter our management of MS at… 
Peripheral blood biomarkers in multiple sclerosis.
TLDR
The availability of reliable biomarkers could radically alter the management of MS at critical phases of the disease spectrum, allowing for intervention strategies that may prevent evolution to long-term neurological disability.
Clinical biomarkers in multiple sclerosis.
TLDR
In this review, recent advances in biomarkers identified by clinical measures, genetic markers, serologic markers, cerebrospinal fluid markers, MRI measures and biomarkers associated with therapies are highlighted.
Biofluid biomarkers of amyotrophic lateral sclerosis
TLDR
While most studies into biomarkers for ALS explore single-marker utility, accurate profiling of individuals with ALS is likely to require a panel of complementary biomarkers providing insight into multiple aspects of the disease.
Cognitive Dysfunction in the Early Stages of Multiple Sclerosis—How Much and How Important?
TLDR
Cognitive impairment early in the course of MS is suggested as a prognostic factor for disease progression, however, clear-cut definitions of the early stage of MS as well as unified criteria for the diagnosis of cognitive impairment are still lacking.
Gene expression signatures: biomarkers toward diagnosing multiple sclerosis
TLDR
Results indicate that gene-expression differences in blood accurately exclude or include a diagnosis of MS and suggest that these approaches may provide clinically useful prediction of MS.
Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
TLDR
The current state of research on differences in miRNA panel expression between the phases of multiple sclerosis is addressed, which may allow for deterring disability progression through successful treatment.
Early Diagnosis of Multiple Sclerosis Based on Optical and Electrochemical Biosensors: Comprehensive Perspective
Multiple Sclerosis (MS) involves an immune-mediated response in which body’s immune system destructs the protective sheath (myelin). Part of the known MS biomarkers are discovered in cerebrospinal
...
1
2
3
4
...

References

SHOWING 1-10 OF 219 REFERENCES
Identification of molecular biomarkers for multiple sclerosis.
Multiple sclerosis is a demyelinating disease of the central nervous system with a presumed autoimmune etiology. Previous microarray analyses identified conserved gene expression signatures in
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.
TLDR
Analysis of antibodies against MOG and MBP in patients with a clinically isolated syndrome is a rapid, inexpensive, and precise method for the prediction of early conversion to clinically definite multiple sclerosis.
Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis
TLDR
This study showed similar CSF tau concentrations in MS patients with different clinical characteristics, suggesting that tau protein does not seem to be a useful routine clinical marker of axonal damage.
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
TLDR
Serum antibodies against MOG and MBP, as detected by Western blot analysis, are not associated with an increased risk of progression to clinically definite multiple sclerosis in patients who have had a clinically isolated syndrome suggestive of multiple sclerosis.
Cerebrospinal fluid proteome profile in multiple sclerosis
TLDR
Though the pathophysiological role of these proteins still remains to be elucidated in detail and further validation is needed, these findings may have a relevant impact on the identification of disease-specific markers.
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis
TLDR
The demonstration of unique serum immune signatures linked to different stages and pathologic processes in MS provides an avenue to monitor MS and to characterize immunopathogenic mechanisms and therapeutic targets in the disease.
Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis
TLDR
No significant difference among different subtypes of MS could be detected, although highest levels were found in very early disease stages and a tendency towards higher CSF tau levels in patients with pronounced intrathecal IgG synthesis is supported, supporting the notion that axonal damage is influenced by inflammatory activity.
Epidemiology and natural history of multiple sclerosis: new insights
TLDR
Understanding of the contributions of specific genetic and environmental factors that contribute to multiple sclerosis has improved and further refinements will eventually allow powerful longitudinal studies to assess genetic andEnvironmental interactions with implications for prediction of individual disease susceptibility, clinical course, and response to therapy.
Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS
TLDR
The data support the prognostic value of anti-myelin antibodies in CIS patients at risk of CDMS, with positive patients showing shorter time interval to relapse occurrence than negative patients.
Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
TLDR
Cerebrospinal fluid osteopontin levels do not correlate with disability in MS but tend to be higher in patients with active disease, and Elevated CSF osteopontein levels are not a specific marker for MS, as they are found in Patients with ONDs and nonneurological illnesses.
...
1
2
3
4
5
...